首頁 › 急性雙表型白血病 › 德克薩斯州 › Dallas
Dallas, TX 的 急性雙表型白血病 臨床試驗
6 項針對 急性雙表型白血病 的研究正在 Dallas(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
招募中1 期
- UT Southwestern/Simmons Cancer Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- University of Texas, Southwestern, Dallas
其他城市的 急性雙表型白血病 試驗
- Seattle, WA15 項研究
- Houston, TX11 項研究
- New York City, NY10 項研究
- Atlanta, GA9 項研究
- Durham, NC8 項研究
- Memphis, TN7 項研究
- Chicago, IL7 項研究
- Charlotte, NC6 項研究
- Baldwin Park, CA6 項研究
- Aurora, CO6 項研究
- Philadelphia, PA6 項研究
- Portland, OR6 項研究
Dallas 的其他研究
- 乳癌55 項研究
- 非小細胞肺癌52 項研究
- 轉移性癌症42 項研究
- 心臟衰竭42 項研究
- 癌症(所有類型)37 項研究
- 前列腺癌36 項研究
- 大腸直腸癌33 項研究
- 肥胖症30 項研究
- 卵巢癌28 項研究
- 肺癌27 項研究
- 膀胱癌27 項研究
- 子宮內膜癌24 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。